Calcimimetics Adherence and Preference in the Management of Uremic Secondary Hyperparathyroidism (SHPT) in Europe

被引：0

作者：

Nduka, Chidozie U. ^{[1
]}

Louie, Karly S. ^{[1
]}

Taylor, Jo ^{[2
]}

Hall, Matt ^{[3
]}

Aucella, Filippo ^{[4
]}

Torres, Pablo A. Urena ^{[5
,6
]}

Labriola, Laura ^{[7
]}

Evenepoel, Pieter ^{[8
]}

Ma, Junjie ^{[12
]}

Saleem, Najma ^{[12
]}

Pisoni, Ronald L. ^{[9
]}

Fouqueray, Bruno L. ^{[10
]}

Horne, Robert ^{[11
]}

机构：

[1] Amgen Inc, Uxbridge, Middx, England

[2] Dorset Cty Hosp NHS Fdn Trust, Dorchester, England

[3] Nottingham Univ Hosp NHS Trust, Nottingham, England

[4] Fdn IRCCS Casa Sollievo Sofferenza, San Giovanni Rotondo, Italy

[5] AURA Paris Nord, St Ouen, France

[6] Univ Paris 05, Necker Hosp, Paris, France

[7] Catholic Univ Louvain, Clin Univ St Luc, Dept Nephrol, Brussels, Belgium

[8] Univ Hosp Leuven, Div Nephrol, Dept Immunol & Microbiol, Leuven, Belgium

[9] Arbor Res Collaborat Hlth, Ann Arbor, MI USA

[10] Amgen GmbH, Rotkreuz, Switzerland

[11] UCL, Sch Pharm, London, England

[12] Amgen Inc, Thousand Oaks, CA USA

来源：

JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY | 2022年 / 33卷 / 11期

关键词：

D O I：

暂无

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

SA-PO325

引用

页码：694 / 694

页数：1

共 50 条

[1] CALCIMIMETIC ADHERENCE AND PREFERENCE IN THE MANAGEMENT OF SECONDARY HYPERPARATHYROIDISM IN EUROPE: A PILOT STUDY
Louie, Karly
Nduka, Chidozie
Taylor, Jo
Hall, Matthew
Aucella, Filippo
Artero, Josep
Na, Pablo Ure
Labriola, Laura
Andersson, Per-Olof
Evenepoel, Pieter
Oliva, Juan Carlos Gonzalez
Pisoni, Ronald
Fouqueray, Bruno
Horne, Robert
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2021, 36
[2] Use of calcimimetics in uremic patients with secondary hyperparathyroidism:: Review
Ureña, P
ARTIFICIAL ORGANS, 2003, 27 (09) : 759 - 764
[3] Calcimimetics for the therapy of secondary hyperparathyroidism
Fiedler, R.
OSTEOLOGIE, 2008, 17 (03) : 148 - 153
[4] Calcimimetics and the treatment of primary and secondary hyperparathyroidism
Joy, MS
Kshirsagar, AV
Franceschini, N
ANNALS OF PHARMACOTHERAPY, 2004, 38 (11) : 1871 - 1880
[5] Parathyroidectomy for Secondary Hyperparathyroidism in the Era of Calcimimetics
Tominaga, Yoshihiro
Matsuoka, Susumu
Uno, Nobuaki
Sato, Tetsuhiko
THERAPEUTIC APHERESIS AND DIALYSIS, 2008, 12 : S21 - S26
[6] Impact of calcimimetics in surgery of secondary hyperparathyroidism
Ruiz, Jose
Rios, Antonio
Manuel Rodriguez, Jose
Llorente, Santiago
Miguel Hernandez, Antonio
Parrilla, Pascual
ENDOCRINOLOGIA DIABETES Y NUTRICION, 2017, 64 (01): : 59 - 61
[7] The place of calcium and calcimimetics in the treatment of secondary hyperparathyroidism
Drüeke, TB
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2001, 16 : 15 - 17
[8] Clinical outcomes in secondary hyperparathyroidism and the potential role of calcimimetics
Cunningham, John
Floege, Juergen
London, Gerard
Rodriguez, Mariano
Shanahan, Catherine M.
CLINICAL KIDNEY JOURNAL, 2008, 1 : I29 - I35
[9] Calcimimetics decrease vascular calcification in uremic rats with severe secondary hyperparathyroidism treated with active vitamin D analogs
Lopez, I.
Aguilera, E.
Mendoza, F. J.
Estepa, J. C.
Perez, J.
Martin, D.
Rodriguez, M.
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2006, 21 : 409 - 410
[10] Calcimimetics for the treatment of secondary hyperparathyroidism in peritoneal dialysis patients
Francis, Jean
Simon, David B.
Jeurgensen, Peter
Finkelstein, Fredric O.
PERITONEAL DIALYSIS INTERNATIONAL, 2008, 28 : S42 - S46

← 1 2 3 4 5 →